Remedy Plan Therapeutics Secures $18M to Revolutionize NAMPT Inhibition and Advance Next-Gen Therapies

Remedy Plan Therapeutics is thrilled to announce a landmark funding raise of $18,000,000 that positions the company for its next phase of innovation and expansion. As a cutting-edge small molecule therapeutics start-up, Remedy Plan Therapeutics is transforming the field of NAMPT inhibition with its pioneering approach to hyperbolic inhibition—a strategy that is not only highly tunable but also minimizes the severe on-target toxicity traditionally associated with NAMPT inhibitors. The fresh capital will accelerate the development of Remedy’s robust pipeline of tunable NAMPT inhibitors that extend promising therapeutic prospects across multiple disease areas, including solid tumors, hematologic malignancies, obesity, and autoimmune disorders. At the forefront of this innovation is Remedy’s lead asset, RPT1G, whose favorable efficacy and tolerability profiles have generated substantial excitement in the clinical research community. With plans to advance RPT1G into clinical trials in 2024, the company is set to redefine treatment paradigms and offer patients novel options where unmet medical needs have persisted. This funding will enable Remedy to bolster its research and development efforts, expand its preclinical and clinical programs, and further optimize its therapeutic candidates to ensure maximum safety and efficacy. It also solidifies the company’s commitment to advancing scientific breakthroughs that address the complex mechanisms of diseases driven by NAMPT dysregulation. As Remedy Plan Therapeutics continues to push the boundaries of medicinal innovation, this investment not only validates its strategic vision but also marks an important step towards revolutionizing patient care in areas that have long awaited targeted, effective treatment alternatives.